论文部分内容阅读
作者采用安慰剂对照研究的方法评估了西沙必利治疗以便秘为主的应激性肠道综合征(IBS)的疗效。 69例患者,随机双盲接受西沙必利5mg或安慰剂,一日3次,连续12周,可根据病情的需要而增减剂量。未用抗胆碱类、神经肽类、胆碱能或其它可影响胃肠运动的药物。根据症状体征及有关检查评价药物的疗效。结果表明,36例经西沙必利8～12周治疗者,每周平均排大便天数为5.3天,而安慰剂组为4.4天,P<0.05,且每周排正常大便天数分别增加至3.5天和1.9天,P<0.05。在12
The authors used a placebo-controlled study to evaluate the efficacy of cisapride in the treatment of constipated predominant irritable bowel syndrome (IBS). Sixty-nine patients were randomized to double-blind cisapride 5mg or placebo, three times a day for 12 weeks, according to the needs of the disease increase and decrease the dose. Did not use anticholinergic, neuropeptides, cholinergic or other drugs that can affect gastrointestinal motility. According to the symptoms and signs and related tests to evaluate the efficacy of drugs. The results showed that 36 patients treated with cisapride for 8 to 12 weeks had a mean bowel movement of 5.3 days per week compared with 4.4 days in the placebo group (P <0.05), and their weekly normal bowel movements increased to 3.5 days And 1.9 days, P <0.05. At 12